



RECEIVED
JUN 17 2003
TECH CENTER
7/2/03

ATTORNEY'S DOCKET NUMBER: 2001180-0051 (HU 1588-98)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Shair et al. Examiner: Tran, M. C. T.
Serial Number: 10/091,240 Art Unit: 1639
Filed: March 5, 2002
For: SYSTEM FOR DETECTING REPORTER GENE EXPRESSION

Mail Stop: DD
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

TRANSMITTAL LETTER

Enclosed are the following documents:

1. Form PTO-1449 (4 pages);
2. Information Disclosure Statement (6 pages);
3. Cited Art (45); and
4. Return Postcard

If any additional fees are required to be paid or if any overpayment has been made, please charge same to Deposit Account No. 03-1721.


Respectfully submitted,

C. Hunter Baker, M.D., Ph.D.
Registration Number: 46,533

Choate, Hall & Stewart
Exchange Place
53 State Street
Boston, MA 02109
(617) 248-5000
Dated: 6/24/03
3576363

Certificate of Mailing	
I certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Assistant Commissioner for Patents, Washington, DC 20231.	
6-24-03	Sandra Saccocia
Date	Signature
Sandra Saccocia	
Typed or Printed Name of person signing certificate	

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



Applicant: Shair et al. Examiner: Tran, M. T.
Serial No.: 10/091,240 Art Unit: 1639
Filing Date: March 5, 2002
Title: SYSTEM FOR DETECTING REPORTER GENE EXPRESSION

RECEIVED
JUN 27 2003
TECHNICAL CENTER 1600/2900

Mail Stop: DD
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicant requests consideration of this Information Disclosure Statement.

Type of Statement

The present Information Disclosure Statement is:

- ☒ An *original* Information Disclosure Statement; or
- ☐ A *supplemental* Information Disclosure Statement.

Certificate of Mailing	
I certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Assistant Commissioner for Patents, Washington, DC 20231.	
6/24/03	<i>Sandra Saccocia</i>
Date	Signature
Sandra Saccocia	
Typed or Printed Name of person signing certificate	

Compliance with 37 CFR § 1.97

The present Information Disclosure Statement is being filed:

- ☒ Pursuant to 37 CFR § 1.97(b); no fee or certification is required:
- ☐ Within three months of the filing date of a national application other than a continued prosecution application under § 1.53(d);
 - ☐ Within three months of the date of entry of the national stage as set forth in § 1.491 in an international application;
 - ☒ Before the mailing of a first Office action on the merits; or
 - ☐ Before the mailing of a first Office action after the filing of a request for continued examination under § 1.114.
- ☐ Pursuant to 37 CFR § 1.97(c) after the dates listed above but before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311, or an action that otherwise closes prosecution in the application; Applicant hereby *either*:
- ☐ Certifies that *either*:
 - ☐ each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement; or
 - ☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the

knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement.; or

☐ Includes herewith the fee set forth in § 1.17(p).

☐ Pursuant to 37 CFR § 1.97(d), after the mailing date of any final action under § 1.113, a notice of allowance under § 1.311, or an action that otherwise closes prosecution in the application; Applicant hereby *both*:

☐ Certifies that *either*:

☐ each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement; or

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement.; and

☐ Includes herewith the fee set forth in § 1.17(p).

Content of the Information Disclosure Statement

Applicant hereby makes of record in the above-identified application the reference(s) listed on the attached form PTO-1449 (modified). The order of presentation of the references should not be construed as an indication of the importance of the references.

Applicant includes copies of references as indicated below:

☒ A copy of each cited reference not indicated with an asterisk is included;

☐ Copies of references indicated with an asterisk on the attached form PTO-1449 are not included pursuant to 37 CFR § 1.98(d) because they were previously provided to the United States Patent Office in an Information Disclosure Statement that complies with 37 CFR § 1.98(a)-(c) and was submitted in the following patent application that is relied upon in the present case for an earlier effective filing date under 35 USC § 120:

Serial Number	Filing Date	Status

☐ Copies of English translations of one or more non-English references are included.

Applicant hereby makes the following additional information of record in the above-identified application:

Applicant certifies that the Information Disclosure Statement *either*:

☐ Does not contain non-English language citations;

☐ Does contain non-English language citations, of which the following is a concise

explanation:

- [] Includes one or more translations of a non-English citation.

Remarks

The submission of this Information Disclosure Statement should not be construed as a representation that a search has been made.

The submission of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in § 1.56(b) .


The submission of this Information Disclosure Statement shall not be construed as a representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
2. The enclosed form PTO-1449 be signed by the Examiner to evidence that the cited patent(s) and publication(s) has (have) been fully considered by the Patent and Trademark Office during the examination of this application; and
3. The citations for the patent(s) and publication(s) be printed on any patent which issues from this application.

Notwithstanding any statements by Applicants, the Examiner is urged to form his or her own conclusions regarding the relevance of the cited reference(s).

Respectfully submitted,



C. Hunter Baker, M.D., Ph.D.
Registration Number: 46,533

CHOATE, HALL & STEWART
Exchange Place
53 State Street
Boston, Massachusetts 02109
(617) 248-5000
(617) 248-4000

Dated: 6/24/03

3576357

Form PTO-1449
(REV. 8-83)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket:
2001180-0051

In re Application No.
10/091,240

Applicant: Shair *et al.*

Filing Date:
March 5, 2002

Group: 1639

**SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT**

U. S. PATENT DOCUMENTS

Examiner's Initials	U.S. Patent No.	Applicant	Issue Date	Class	Subclass
	5,780,258	de la Brousse et al.	July 14, 1998	435	29
	5,702,903	Kinzler et al.	December 30, 1997	435	6
	5,625,123	Shiho et al.	April 29, 1997	800	2
	5,571,688	Mekalanos et al.	November 5, 1996	435	29
	5,569,588	Ashby et al.	October 29, 1996	435	6
	5,525,490	Erickson et al.	June 11, 1996	435	29
	5,474,929	Pelcher	December 12, 1995	435	240.4
	5,436,131	Condra et al.	July 25, 1995	435	7.4

U.S. PATENT APPLICATIONS

Examiner's Initials	Serial No. or Publication No.	Applicant	Filing Date		

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Document No.	Country	Date	Translation	
				Yes	No

Examiner's
Initials

**OTHER DOCUMENTS
(Including Author, Title, Date, Pertinent Pages, Etc.)**

	Baltimore, et al., "Regulation of the NF- κ B/Rel Transcription Factor and I κ B Inhibitor System", <i>Curr. Opin. Biol.</i> 5 :477, 1993.
	Baumann, et al., "Rapid Identification of Phosphopeptide Ligands for SH2 Domains" <i>J. Biol. Chem.</i> 271 : 16500-16505, 1996.
	Crane, et al., "The Structure of Nitric Oxide Synthase Oxygenase Domain and Inhibitor Complexes", <i>Science</i> , 278 : 425-431, 1997.
	Czarnik, "Encoding Methods for Combinatorial Chemistry" <i>Curr. Op. Chem. Biol.</i> , 1 :60-66, 1997.
	Eberhardt, et al., "Molecular Mechanisms of Inducible Nitric Oxide Synthase Gene Expression by IL-1 β and cAMP in Rat Mesangial Cells", <i>The Journal of Immunology</i> , 160 : 4961-4969,

Form PTO-1449
(REV. 8-83)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket:
2001180-0051

In re Application No.
10/091,240

Applicant: Shair *et al.*

Filing Date:
March 5, 2002

Group: 1639

1998.

Feldman, et al., "Small, Reactive, and Containing No Carbon Atoms, Nitric Oxide is Nevertheless Emerging as a Biochemical of Major Importance", *Chemical and Engineering News*, 26-38, 1993.

Fruchtel, et al., "Organic Chemistry on Solid Supports" *Angew Chem. Int. Ed. Engl.* **35**:17-42, 1996.

Furka, et al., "General Method for Rapid Synthesis of Multicomponent Peptide Mixtures" *Int. J. Pept. Protein Res.* **37**: 487-493, 1991.

Gallop, et al., "Generation and Screening of an Oligonucleotide-Encoded Synthetic Peptide Library" *Proc. Natl. Acad. Sci. USA*, **90**: 10700-10704, 1993.

Gibaldi, M., "What is Nitric Oxide and Why Are So Many People Studying it?", *J. Clin. Pharmacol.* **33**: 488-496, 1993.

Goldring, et al., "In Vivo Footprinting of the Mouse Inducible Nitric Oxide Synthase Gene: Inducible Protein Occupation of Numerous Sites Including Oct and NF-IL6", *Nucleic Acids Research*, **24**(9): 1682-1687, 1996.

Goldring, et al., "Transcriptional Inhibition of the Inducible Nitric Oxide Synthase Gene by Competitive Binding of NF- κ B/REL Proteins", *Biochemical and Biophysical Research Communications*, **209**(1): 73-79, 1995.

Grisham, et al., "Effects of Aminosalicylates and Immunosuppressive Agents on Nitric Oxide-Dependent N-Nitrosation Reactions", *Biochemical Pharmacology*, **47**(10): 1897-1902, 1994.

Hevel, et al., "Purification of the Inducible Murine Macrophage Nitric Oxide Synthase" *J. Biol. Chem.*, **266**: 22789-22791, 1991.

Jaffrey, et al., "PIN: An Associated Protein Inhibitor of Neuronal Nitric Oxide Synthase" *Science*, **274**: 774-777, 1996.

Janssens, et al., "Cloning and Expression of a cDNA Encoding Human Endothelium-Derived Relaxing Factor/Nitric Oxide Synthase", *The Journal of Biological Chemistry*, **267**(21): 14519-14522, 1992.

Kojima, et al., "Detection and Imaging of Nitric Oxide with Novel Fluorescent Indicators: Diaminofluoresceins", *Analytical Chemistry*, 1-8.

Kojima, et al., "Development of a Fluorescent Indicator for Nitric Oxide Based on the Fluorescein Chromophore" *Chem. Pharm. Bull.*, **46**: 373-375, 1998.


Koshland, "The Molecule of the Year" *Science*, **258**: 1861, 1992.

Kuo, et al., "Oxidative Stress Increases Hepatocyte iNOS Gene Transcription and Promoter Activity", *Biochemical and Biophysical Research Communications*, **234**: 289-292, 1997.

Lowenstein, et al., "Macrophage Nitric Oxide Synthase Gene: Two Upstream Regions Mediate Induction by Interferon γ and Lipopolysaccharide", *Proc. Natl. Acad. Sci. USA*, **90**: 9730-9734, 1993.

JUN 27 2003

TECH CENTER 1600/2900

Form PTO-1449
(REV. 8-83)U.S. Department of Commerce
Patent and Trademark OfficeAtty. Docket:
2001180-0051In re Application No.
10/091,240SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENTApplicant: Shair *et al.*Filing Date:
March 5, 2002

Group: 1639

✓ Martin, et al., "Role of Interferon Regulatory Factor 1 in Induction of Nitric Oxide Synthase", *J. Exp. Med.* **180**: 977-984, 1994.

✓ Michel, et al., "Perspective Series: Nitric Oxide and Nitric Oxide Synthases", *J. Clin. Invest.*, **100**(9): 2146-2152, 1997.

✓ Nakatsubo, et al., "Direct Evidence of Nitric Oxide Production from Bovine Aortic Endothelial Cells Using New Fluorescence Indicators: Diaminofluoresceins", *FEBS Letters*, **427**: 263-266, 1998.

✓ Nestler, et al., "A General Method for Molecular Tagging of Encoded Combinatorial Chemistry Libraries" *J. Org. Chem.* **59**: 4723-4726, 1994.

✓ Nunokawa, et al., "Human Inducible Nitric Oxide Synthase Gene is Transcriptionally Regulated by Nuclear Factor- κ B Dependent Mechanism", *Biochemical and Biophysical Research Communications*, **223**: 347-352, 1996.

✓ Nunokawa, et al., "Expression of Human Inducible Nitric Oxide Synthase is Regulated by Both Promoter and 3'-Regions", *Biochemical and Biophysical Research Communications*, **233**: 523-526, 1997.

✓ Oguchi, et al., "Enhancement of Inducible-Type NO Synthase Gene Transcription by Protein Synthesis Inhibitors", Activation of an Intracellular Signal Transduction Pathway by Low Concentrations of Cycloheximide", *FEBS Letters*, **338**: 326-330, 1994.

✓ Peng, et al., "Nitric Oxide Inhibits Macrophage-Colony Stimulating Factor Gene Transcription in Vascular Endothelial Cells", *The Journal of Biological Chemistry*, **270**(28): 17050-17055, 1995.

✓ Sari, et al., "Expression in Yeast and Purification of Functional Macrophage Nitric Oxide Synthase. Evidence for Cysteine-194 As Iron Proximal Ligand", *Biochemistry*, **35**: 7204-7213, 1996.

✓ Smith, et al., "Simple Alkanethiol Groups for Temporary Blocking of Sulfhydryl Groups of Enzymes", *Biochemistry*, **14**: 766-771, 1975.

✓ Thompson, et al., "Synthesis and Applications of Small Molecule Libraries" *Chem. Rev.* **96**: 555-600, 1996.

✓ Tan, et al., "Stereoselective Synthesis of Over Two Million Compounds Having Structural Features Both Reminiscent of Natural Products and Compatible with Miniaturized Cell-Based Assays", *J. Am. Chem. Soc.*, **120**: 8565-8570, 1998.


✓ Venema, et al., "Organization of the Bovine Gene Encoding the Endothelial Nitric Oxide Synthase", *Biochimica et Biophysica Acta*, **1218**: 413-420, 1994.

✓ Weinberg, "The Retinoblastoma Protein and Cell Cycle Control" *Cell*, **81**: 323-330, 1995.

✓ Wong, et al., "The Heat Shock Response Inhibits Inducible Nitric Oxide Synthase Gene Expression by Blocking I κ -B Degradation and NF- κ B Nuclear Translocation", *Biochemical and Biophysical Research Communications*, **231**: 257-263, 1997.

✓ Xie, et al., "Role of Transcription Factor NF- κ B/Rel in Induction of Nitric Oxide Synthase", *The Journal of Biological Chemistry*, **269**(7): 4705-4708, 1994.

JUN 27 2003

Form PTO-1449 (REV. 8-83)	 U.S. Department of Commerce Patent and Trademark Office	TECH CENTER 1600/2800 Att. Docket: 2001180-0051	In re Application No. 10/091,240
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT		Applicant: Shair <i>et al.</i>	
		Filing Date: March 5, 2002	Group: 1639
EXAMINER		DATE CONSIDERED	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

3570099